We are live on ! Find out more
Cambridge Investment Research Advisors

Cambridge Investment Research Advisors Portfolio holdings

AUM $44.6B
1-Year Est. Return 28.94%
This Fund
S&P 500
This Quarter Est. Return
+3.09%
1 Year Est. Return
+28.94%
3 Year Est. Return
+82.62%
5 Year Est. Return
+90.41%
10 Year Est. Return
+293.66%
AUM
$27.1B
AUM Growth
+$1.07B
Cap. Flow
+$498M
Cap. Flow %
1.84%
Top 10 Hldgs %
21.61%
Holding
3,481
New
179
Increased
1,545
Reduced
1,498
Closed
172
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TE
3226
T1 Energy
TE
$1.37B
$45K ﹤0.01%
26,320
+10,119
+62% +$19.3K
GOEV
3227
DELISTED
Canoo Inc. Class A Common Stock
GOEV
$45K ﹤0.01%
1,048
+16
+2% +$783
PZG icon
3228
Paramount Gold Nevada
PZG
$130M
$44K ﹤0.01%
110,648
+5,000
+5% +$2.3K
VBIV
3229
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$44K ﹤0.01%
67,113
-16,969
-20% -$10.6K
NNDM
3230
Nano Dimension
NNDM
$343M
$43K ﹤0.01%
19,376
-250
-1% -$627
AUR icon
3231
Aurora
AUR
$13.5B
$41K ﹤0.01%
+14,948
New +$41.4K
FCEL icon
3232
FuelCell Energy
FCEL
$1.73B
$41K ﹤0.01%
2,154
+648
+43% +$17.4K
SLI
3233
Standard Lithium
SLI
$594M
$41K ﹤0.01%
33,192
-8,329
-20% -$11.6K
ONL
3234
Orion Office REIT
ONL
$161M
$40K ﹤0.01%
11,135
-1,034
-8% -$3.54K
LWLG icon
3235
Lightwave Logic
LWLG
$1.23B
$39K ﹤0.01%
12,961
NAK
3236
Northern Dynasty Minerals
NAK
$953M
$38K ﹤0.01%
123,060
+4,000
+3% +$1.2K
PHX
3237
DELISTED
PHX Minerals
PHX
$38K ﹤0.01%
11,756
+586
+5% +$1.93K
GTHX
3238
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$38K ﹤0.01%
16,711
-100
-0.6% -$382
EOSE icon
3239
Eos Energy Enterprises
EOSE
$1.54B
$37K ﹤0.01%
29,400
+8,200
+39% +$6.78K
TSHA icon
3240
Taysha Gene Therapies
TSHA
$2.05B
$37K ﹤0.01%
16,505
-785
-5% -$2.28K
OXSQ icon
3241
Oxford Square Capital
OXSQ
$166M
$35K ﹤0.01%
11,855
+144
+1% +$449
QSI icon
3242
Quantum-Si Incorporated
QSI
$182M
$35K ﹤0.01%
33,355
CHRS icon
3243
Coherus Oncology
CHRS
$181M
$34K ﹤0.01%
19,585
-5,058
-21% -$10.2K
DHC
3244
Diversified Healthcare Trust
DHC
$2.02B
$33K ﹤0.01%
10,906
+29
+0.3% +$74
AWRE icon
3245
Aware
AWRE
$26M
$31K ﹤0.01%
+15,582
New +$28.9K
LDI icon
3246
loanDepot
LDI
$298M
$31K ﹤0.01%
18,693
+5,258
+39% +$11.2K
REKR icon
3247
Rekor Systems
REKR
$94M
$30K ﹤0.01%
19,295
-300
-2% -$525
SOHO
3248
DELISTED
Sotherly Hotels
SOHO
$30K ﹤0.01%
25,708
-2,500
-9% -$3.29K
SPWR
3249
DELISTED
SunPower Corporation Common Stock
SPWR
$30K ﹤0.01%
+10,021
New +$27.4K
CUE icon
3250
Cue Biopharma
CUE
$128M
$28K ﹤0.01%
740

Similar funds

Cambridge Investment Research Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, Cambridge Investment Research Advisors held 3,481 positions worth $27.1B, up 4.1% from $26B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Cambridge Investment Research Advisors's Q2 2024 filing shows 179 new, 1,545 increased, 1,498 reduced and 172 closed positions. Its largest new stake was Sila Realty Trust: 733,789 shares worth $15.5M. The largest sale was Invesco QQQ Trust, an estimated $99.4M.

By sector, the portfolio is most concentrated in Technology at 12% of assets, up from 11% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Cambridge Investment Research Advisors's largest Q2 2024 buy was Sila Realty Trust: 733,789 shares worth $15.5M.
  • Cambridge Investment Research Advisors added most to PIMCO Enhanced Short Maturity Active Exchange-Traded Fund in Q2 2024, an estimated $77.4M increase.
  • Cambridge Investment Research Advisors's biggest Q2 2024 reduction was Invesco QQQ Trust, cutting an estimated $99.4M.
  • Cambridge Investment Research Advisors fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $4.55M.
  • Cambridge Investment Research Advisors's ten largest holdings make up 22% of its $27.1B portfolio in Q2 2024.
  • Cambridge Investment Research Advisors opened 179 new positions and closed 172 in Q2 2024.
  • Cambridge Investment Research Advisors's portfolio value rose 4.1% quarter-over-quarter to $27.1B.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2024, filed 26 Jul 2024.